Inclusion Criteria: - Histologically confirmed NSCLC with activated PI3K pathway - Progressive disease after prior systemic antineoplastic treatment(s) for advanced NSCLC - Archival or fresh tumor biopsy must be available for profiling - Measurable and/or non-measurable disease as per RECIST 1.1 criteria - Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 - Adequate organ function as assessed by laboratory tests Exclusion Criteria: - Patient has received previous treatment with PI3K inhibitors - Patient with squamous NSCLC has received more than one line of chemotherapy treatment for metastatic disease; patient with non-squamous NSCLC has received more than two lines of systemic antineoplastic treatment for metastatic disease - Uncontrolled or symptomatic CNS metastases - Concurrent use of any other approved or investigational antineoplastic agent - Radiotherapy ≤ 28 days prior to starting study drug - Major surgery within 28 days prior to starting study drug - History of clinically significant cardiac dysfunction, mood disorders, or poorly controlled diabetes mellitus - Current treatment with medication that has a known risk to prolong the QT interval or inducing Torsades de Pointes - Impairment of gastrointestinal (GI) function - Chronic treatment with steroids or another immunosuppressive agent. - Concurrent severe and/or uncontrolled medical condition - Currently receiving Warfarin or another coumarin derivative - Known history of HIV infection - Sensory neuropathy with functional impairment (CTC grade 2 neuropathy, regardless of causality) - Pregnancy, lactation, or breastfeeding - Woman of child-bearing potential Other protocol-defined inclusion/exclusion criteria may apply